A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib cohort, Open-label, Single arm for patients with unresected stage I/II, lymph negative NSCLC harboring a sensitizing EGFR mutation

lymph done negative NSCLC harboring a sensitizing EGFR mutation, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Main cohort: Patients with unresected Stage I/II, Single arm for patients with unresected stage I/II

Applicable to main cohort: PFS in patients with subset of T1 to T3N0M0 by BICR, Applicable to osimertinib cohort: 4-years PFS by ICR using RECIST 1.1

Applicable to main cohort: PFS in patients with T1 to T3N0M0 NSCLC; Overall Survival; PFS24, TTP, and TTDM using BICR assessments according to RECIST 1.1; PFS2 using local assessment; PK of durvalumab in serum; Presence of ADA for durvalumab; EORTC QLQ-C30: Change in symptoms, functioning, and global health status/quality of life; Safety and tolerability:AEs, physical examinations, vital signs, electrocardiograms, and laboratory findings, Applicable to osimertinib cohort: AEs (graded by CTCAE version 5); Laboratory studies: chemistry, hematology, and urinalysis; Clinical evaluations; ECG parametres; LVEF; WHO performance status; PFS using RECIST 1.1; OS; Site(s) of disease progression; Time to CNS progression; TTP; PFS2

No related papers found yet.

Belgium, France, Germany, Greece, Italy, Netherlands, Poland, Spain